Guizhou Sanli Pharmaceutical Co Ltd (603439) — Net Asset Quality Index
Guizhou Sanli Pharmaceutical Co Ltd (603439) has a Net Asset Quality Index of 54.4% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.85 Billion minus total liabilities of CN¥1.30 Billion yields net assets of CN¥1.55 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check how resilient are Guizhou Sanli Pharmaceutical Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Guizhou Sanli Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2013–2024)
This chart shows how Guizhou Sanli Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 12 annual periods from 2013 to 2024. As of September 2025, the index stands at 54.4%, representing net assets of CN¥1.55 Billion against total assets of CN¥2.85 Billion CNY. See Guizhou Sanli Pharmaceutical Co Ltd (603439) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Guizhou Sanli Pharmaceutical Co Ltd (2013–2024)
The table below presents the year-by-year Net Asset Quality Index for Guizhou Sanli Pharmaceutical Co Ltd from 2013 to 2024, covering 12 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market value of Guizhou Sanli Pharmaceutical Co Ltd.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 50.0% | CN¥1.59 Billion | CN¥3.19 Billion | CN¥1.60 Billion | ▼ -8.6 pp |
| 2023 | 58.5% | CN¥1.71 Billion | CN¥2.92 Billion | CN¥1.21 Billion | ▼ -9.6 pp |
| 2022 | 68.2% | CN¥1.24 Billion | CN¥1.82 Billion | CN¥578.40 Million | ▼ -5.3 pp |
| 2021 | 73.5% | CN¥1.03 Billion | CN¥1.40 Billion | CN¥372.93 Million | ▼ -4.5 pp |
| 2020 | 78.0% | CN¥981.88 Million | CN¥1.26 Billion | CN¥276.91 Million | ▼ -11.1 pp |
| 2019 | 89.1% | CN¥651.09 Million | CN¥730.81 Million | CN¥79.72 Million | ▼ -0.7 pp |
| 2018 | 89.8% | CN¥518.02 Million | CN¥576.70 Million | CN¥58.69 Million | ▲ +6.1 pp |
| 2017 | 83.7% | CN¥473.36 Million | CN¥565.43 Million | CN¥92.07 Million | ▲ +0.6 pp |
| 2016 | 83.1% | CN¥430.59 Million | CN¥518.02 Million | CN¥87.44 Million | ▲ +11.6 pp |
| 2015 | 71.5% | CN¥216.53 Million | CN¥302.67 Million | CN¥86.14 Million | ▲ +27.7 pp |
| 2014 | 43.8% | CN¥108.92 Million | CN¥248.58 Million | CN¥139.67 Million | ▲ +9.2 pp |
| 2013 | 34.6% | CN¥69.09 Million | CN¥199.62 Million | CN¥130.52 Million | — |